A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer

Charles Blanke, J. Shultz, J. Cox, M. Modiano, R. Isaacs, B. Kasimis, R. Schilsky, J. Fleagle, M. Moore, N. Kemeny, D. Carlin, L. Hammershaimb, D. Haller

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Trimetrexate (TMTX) biochemically modulates 5-fluorouracil (5-FU) and leucovorin (LCV). Two phase II trials demonstrated promising activity for TMTX/5-FU/LCV in patients with untreated advanced colorectal cancer (ACC). This trial was designed to demonstrate the safety and efficacy of TMTX/5-FU/LCV as first-line treatment in ACC. Patients and methods: Eligible patients with ACC were randomized in double-blind fashion to receive placebo or TMTX (110 mg/m2) intravenously (i.v.) followed 24 h later by i.v. LCV 200 mg/m2, and 5-FU 500 mg/m2 plus oral LCV rescue. Both schedules were given weekly for 6 weeks every 8 weeks. Patients were evaluated for progression-free survival (PFS), overall survival (OS), tumor response, quality of life (QoL) and toxicity. Results: A total of 382 eligible patients were randomized. Significant toxicities were noted more frequently with TMTX/5-FU/LCV. Diarrhea was the most common grade 3 or 4 side-effect (41% and 28% on the TMTX and placebo arms, respectively). QoL scores and response rates did not differ between treatment arms. PFS was 5.3 months and 4.4 months in the TMTX and placebo arms, respectively (P = 0.77); Wilcoxon). OS was 15.8 months and 16.8 months, respectively (P = 0.73; Wilcoxon). Conclusions: The addition of TMTX to a weekly regimen of 5-FU/LCV worsened grade 3 or 4 diarrhea. The inclusion of TMTX did not yield any significant improvements in response rate, PFS or OS.

Original languageEnglish (US)
Pages (from-to)87-91
Number of pages5
JournalAnnals of Oncology
Volume13
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Trimetrexate
Leucovorin
Fluorouracil
Colorectal Neoplasms
Placebos
Disease-Free Survival
Survival
Diarrhea
Quality of Life
Appointments and Schedules

Keywords

  • 5-fluorouracil
  • Biochemical modulation
  • Colorectal cancer
  • Leucovorin
  • Randomized trial
  • Trimetrexate

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. / Blanke, Charles; Shultz, J.; Cox, J.; Modiano, M.; Isaacs, R.; Kasimis, B.; Schilsky, R.; Fleagle, J.; Moore, M.; Kemeny, N.; Carlin, D.; Hammershaimb, L.; Haller, D.

In: Annals of Oncology, Vol. 13, No. 1, 2002, p. 87-91.

Research output: Contribution to journalArticle

Blanke, C, Shultz, J, Cox, J, Modiano, M, Isaacs, R, Kasimis, B, Schilsky, R, Fleagle, J, Moore, M, Kemeny, N, Carlin, D, Hammershaimb, L & Haller, D 2002, 'A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer', Annals of Oncology, vol. 13, no. 1, pp. 87-91. https://doi.org/10.1093/annonc/mdf043
Blanke, Charles ; Shultz, J. ; Cox, J. ; Modiano, M. ; Isaacs, R. ; Kasimis, B. ; Schilsky, R. ; Fleagle, J. ; Moore, M. ; Kemeny, N. ; Carlin, D. ; Hammershaimb, L. ; Haller, D. / A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. In: Annals of Oncology. 2002 ; Vol. 13, No. 1. pp. 87-91.
@article{dbc7a2847ba04a8e96dfa778f1ebae25,
title = "A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer",
abstract = "Background: Trimetrexate (TMTX) biochemically modulates 5-fluorouracil (5-FU) and leucovorin (LCV). Two phase II trials demonstrated promising activity for TMTX/5-FU/LCV in patients with untreated advanced colorectal cancer (ACC). This trial was designed to demonstrate the safety and efficacy of TMTX/5-FU/LCV as first-line treatment in ACC. Patients and methods: Eligible patients with ACC were randomized in double-blind fashion to receive placebo or TMTX (110 mg/m2) intravenously (i.v.) followed 24 h later by i.v. LCV 200 mg/m2, and 5-FU 500 mg/m2 plus oral LCV rescue. Both schedules were given weekly for 6 weeks every 8 weeks. Patients were evaluated for progression-free survival (PFS), overall survival (OS), tumor response, quality of life (QoL) and toxicity. Results: A total of 382 eligible patients were randomized. Significant toxicities were noted more frequently with TMTX/5-FU/LCV. Diarrhea was the most common grade 3 or 4 side-effect (41{\%} and 28{\%} on the TMTX and placebo arms, respectively). QoL scores and response rates did not differ between treatment arms. PFS was 5.3 months and 4.4 months in the TMTX and placebo arms, respectively (P = 0.77); Wilcoxon). OS was 15.8 months and 16.8 months, respectively (P = 0.73; Wilcoxon). Conclusions: The addition of TMTX to a weekly regimen of 5-FU/LCV worsened grade 3 or 4 diarrhea. The inclusion of TMTX did not yield any significant improvements in response rate, PFS or OS.",
keywords = "5-fluorouracil, Biochemical modulation, Colorectal cancer, Leucovorin, Randomized trial, Trimetrexate",
author = "Charles Blanke and J. Shultz and J. Cox and M. Modiano and R. Isaacs and B. Kasimis and R. Schilsky and J. Fleagle and M. Moore and N. Kemeny and D. Carlin and L. Hammershaimb and D. Haller",
year = "2002",
doi = "10.1093/annonc/mdf043",
language = "English (US)",
volume = "13",
pages = "87--91",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer

AU - Blanke, Charles

AU - Shultz, J.

AU - Cox, J.

AU - Modiano, M.

AU - Isaacs, R.

AU - Kasimis, B.

AU - Schilsky, R.

AU - Fleagle, J.

AU - Moore, M.

AU - Kemeny, N.

AU - Carlin, D.

AU - Hammershaimb, L.

AU - Haller, D.

PY - 2002

Y1 - 2002

N2 - Background: Trimetrexate (TMTX) biochemically modulates 5-fluorouracil (5-FU) and leucovorin (LCV). Two phase II trials demonstrated promising activity for TMTX/5-FU/LCV in patients with untreated advanced colorectal cancer (ACC). This trial was designed to demonstrate the safety and efficacy of TMTX/5-FU/LCV as first-line treatment in ACC. Patients and methods: Eligible patients with ACC were randomized in double-blind fashion to receive placebo or TMTX (110 mg/m2) intravenously (i.v.) followed 24 h later by i.v. LCV 200 mg/m2, and 5-FU 500 mg/m2 plus oral LCV rescue. Both schedules were given weekly for 6 weeks every 8 weeks. Patients were evaluated for progression-free survival (PFS), overall survival (OS), tumor response, quality of life (QoL) and toxicity. Results: A total of 382 eligible patients were randomized. Significant toxicities were noted more frequently with TMTX/5-FU/LCV. Diarrhea was the most common grade 3 or 4 side-effect (41% and 28% on the TMTX and placebo arms, respectively). QoL scores and response rates did not differ between treatment arms. PFS was 5.3 months and 4.4 months in the TMTX and placebo arms, respectively (P = 0.77); Wilcoxon). OS was 15.8 months and 16.8 months, respectively (P = 0.73; Wilcoxon). Conclusions: The addition of TMTX to a weekly regimen of 5-FU/LCV worsened grade 3 or 4 diarrhea. The inclusion of TMTX did not yield any significant improvements in response rate, PFS or OS.

AB - Background: Trimetrexate (TMTX) biochemically modulates 5-fluorouracil (5-FU) and leucovorin (LCV). Two phase II trials demonstrated promising activity for TMTX/5-FU/LCV in patients with untreated advanced colorectal cancer (ACC). This trial was designed to demonstrate the safety and efficacy of TMTX/5-FU/LCV as first-line treatment in ACC. Patients and methods: Eligible patients with ACC were randomized in double-blind fashion to receive placebo or TMTX (110 mg/m2) intravenously (i.v.) followed 24 h later by i.v. LCV 200 mg/m2, and 5-FU 500 mg/m2 plus oral LCV rescue. Both schedules were given weekly for 6 weeks every 8 weeks. Patients were evaluated for progression-free survival (PFS), overall survival (OS), tumor response, quality of life (QoL) and toxicity. Results: A total of 382 eligible patients were randomized. Significant toxicities were noted more frequently with TMTX/5-FU/LCV. Diarrhea was the most common grade 3 or 4 side-effect (41% and 28% on the TMTX and placebo arms, respectively). QoL scores and response rates did not differ between treatment arms. PFS was 5.3 months and 4.4 months in the TMTX and placebo arms, respectively (P = 0.77); Wilcoxon). OS was 15.8 months and 16.8 months, respectively (P = 0.73; Wilcoxon). Conclusions: The addition of TMTX to a weekly regimen of 5-FU/LCV worsened grade 3 or 4 diarrhea. The inclusion of TMTX did not yield any significant improvements in response rate, PFS or OS.

KW - 5-fluorouracil

KW - Biochemical modulation

KW - Colorectal cancer

KW - Leucovorin

KW - Randomized trial

KW - Trimetrexate

UR - http://www.scopus.com/inward/record.url?scp=0036227995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036227995&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdf043

DO - 10.1093/annonc/mdf043

M3 - Article

C2 - 11863117

AN - SCOPUS:0036227995

VL - 13

SP - 87

EP - 91

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -